Health Care

Entera Bio CEO’s RSU grant boosts insider confidence and signals optimism for phase‑3 trials, potentially lifting stock toward its 52‑week high.

Cardiff Oncology’s insider buying surge signals confidence amid a low‑price offering, highlighting potential upside for value‑seeking investors in the biotech sector.

Investor insight: Traws Pharma’s latest insider stock‑option award signals CEO confidence in its oncology pipeline and a bullish long‑term outlook.

Insider buying surge shows confidence in Vivani’s NanoPortal drug‑implant platform – discover why investors are backing the company.

Insider buying of Anixa Biosciences shares signals confidence in its breast‑cancer vaccine pipeline and upcoming clinical milestones, hinting at future upside.

Inside Traws Pharma: Werner’s 14,150‑share option grant signals insider optimism on the company’s drug pipeline, hinting at a potential stock rally if key milestones hit.

Richard Chen’s insider trade shows confidence in Personalis’ growth, highlighting UKCA certification, expanding MRD pipeline, and AI‑driven diagnostics that could lift the undervalued stock.

Explore how Natera’s insider sales intersect with precision‑medicine trends, reimbursement tactics, and tech adoption—unpacking investor sentiment and future growth.

Mineralys Therapeutics CEO’s July 13, 2026 block sale shows a rule‑based divestment amid strong Phase IIa safety data for its aldosterone synthase inhibitor, MST‑001, and pending orphan drug approval.

Oruka Therapeutics insider trades by CMO Joana Gonçalves show disciplined buy‑low, sell‑high activity that signals leadership confidence and long‑term upside for the company.